OTC Pharmaceuticals in Poland

Date: September 18, 2014
Pages: 33
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Brief Review
Delivery: E-mail Delivery (PDF)
ID: O08D372F604EN
Leaflet:

Download PDF Leaflet

OTC Pharmaceuticals in Poland
INTRODUCTION

OTC Pharmaceuticals in Poland industry profile provides top-line qualitative and quantitative summary information including: market size (value 2009-13, and forecast to 2018). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Poland otc pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

HIGHLIGHTS
  • The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin and other analgesics), and medicated skin products (anti-bacterials, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2013 annual average exchange rates.
  • The Polish OTC pharmaceuticals market had total revenues of $3,487.6m in 2013, representing a compound annual growth rate (CAGR) of 6.6% between 2009 and 2013.
  • The traditional medicines segment was the market's most lucrative in 2013, with total revenues of $773.3m, equivalent to 22.2% of the market's overall value.
  • The performance of the market is forecast to accelerate, with an anticipated CAGR of 10.6% for the five-year period 2013 - 2018, which is expected to drive the market to a value of $5,779.1m by the end of 2018.
FEATURES
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the otc pharmaceuticals market in Poland
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Poland
  • Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Poland otc pharmaceuticals market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Poland economy

KEY QUESTIONS ANSWERED
  • What was the size of the Poland otc pharmaceuticals market by value in 2013?
  • What will be the size of the Poland otc pharmaceuticals market in 2018?
  • What factors are affecting the strength of competition in the Poland otc pharmaceuticals market?
  • How has the market performed over the last five years?
Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market share
Market distribution
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Aflofarm Farmacja Polska Sp. z o.o.
GlaxoSmithKline Plc
Johnson & Johnson
USP Zdrowie Sp. z o.o.
Macroeconomic Indicators
Country Data
Appendix
Methodology
Industry associations
Related MarketLine research

LIST OF TABLES

Table 1: Poland OTC pharmaceuticals market value: $ million, 2009–13
Table 2: Poland OTC pharmaceuticals market category segmentation: $ million, 2013
Table 3: Poland OTC pharmaceuticals market geography segmentation: $ million, 2013
Table 4: Poland OTC pharmaceuticals market share: % share, by value, 2013
Table 5: Poland OTC pharmaceuticals market distribution: % share, by value, 2013
Table 6: Poland OTC pharmaceuticals market value forecast: $ million, 2013–18
Table 7: Aflofarm Farmacja Polska Sp. z o.o.: key facts
Table 8: GlaxoSmithKline Plc: key facts
Table 9: GlaxoSmithKline Plc: key financials ($)
Table 10: GlaxoSmithKline Plc: key financials (?)
Table 11: GlaxoSmithKline Plc: key financial ratios
Table 12: Johnson & Johnson: key facts
Table 13: Johnson & Johnson: key financials ($)
Table 14: Johnson & Johnson: key financial ratios
Table 15: USP Zdrowie Sp. z o.o.: key facts
Table 16: Poland size of population (million), 2009–13
Table 17: Poland gdp (constant 2005 prices, $ billion), 2009–13
Table 18: Poland gdp (current prices, $ billion), 2009–13
Table 19: Poland inflation, 2009–13
Table 20: Poland consumer price index (absolute), 2009–13
Table 21: Poland exchange rate, 2009–13

LIST OF FIGURES

Figure 1: Poland OTC pharmaceuticals market value: $ million, 2009–13
Figure 2: Poland OTC pharmaceuticals market category segmentation: % share, by value, 2013
Figure 3: Poland OTC pharmaceuticals market geography segmentation: % share, by value, 2013
Figure 4: Poland OTC pharmaceuticals market share: % share, by value, 2013
Figure 5: Poland OTC pharmaceuticals market distribution: % share, by value, 2013
Figure 6: Poland OTC pharmaceuticals market value forecast: $ million, 2013–18
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Poland, 2013
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Poland, 2013
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Poland, 2013
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Poland, 2013
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Poland, 2013
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Poland, 2013
Figure 13: GlaxoSmithKline Plc: revenues & profitability
Figure 14: GlaxoSmithKline Plc: assets & liabilities
Figure 15: Johnson & Johnson: revenues & profitability
Figure 16: Johnson & Johnson: assets & liabilities
Skip to top


OTC Pharmaceuticals Global Industry Almanac_2016 US$ 2,995.00 Oct, 2016 · 491 pages
OTC Pharmaceuticals in the United Kingdom US$ 350.00 Sep, 2016 · 38 pages
Global OTC Pharmaceuticals US$ 350.00 Sep, 2016 · 38 pages
OTC Pharmaceuticals in Belgium US$ 350.00 Sep, 2014 · 38 pages

Ask Your Question

OTC Pharmaceuticals in Poland
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: